Las células dendríticas CD11c+ aceleran el rechazo de los trasplantes cardíacos más antiguos a través de la

Rupert Oberhuber1, Timm Heinbokel1, Hector Rodriguez Cetina Biefer1

  • 1From Transplantation Surgery Research Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.O., T.H., H.R.C.B., K.H., K.E., H.U., M.Q., F.V., F.K., B.S., A.E., S.G.T.); Department of Visceral, Transplant, and Thoracic Surgery, Center for Operative Medicine, Innsbruck Medical University, Austria (R.O.); Institute of Medical Immunology (T.H.) and Department for General, Visceral, Transplant, Vascular, and Thorax Surgery (J.P.), Charité-Universitätsmedizin Berlin, Germany; Clinic for Cardiovascular Surgery, University Hospital Zurich, Switzerland (H.R.C.B., M.J.W.); Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA (O.B., R.A.); Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (O.B.); Division of Transplantation, Department of Surgery, Medical University of Vienna, Austria (K.H.); Rodent Histopathology Core, Harvard Medical School, Boston, MA (R.T.B.); Research Institute for Biomedical Sciences, Tokyo University of Science, Noda, Chiba, Japan (R.T.B.); Department of Visceral, Transplantation, Thoracic, and Vascular Surgery, University Hospital of Leipzig, Germany (M.Q., F.K.); and Division of Transplant Surgery, Department of Surgery, Erasmus MC-University Medical Center, Rotterdam, The Netherlands (B.S.).

Circulation
|May 10, 2015
PubMed
Resumen

Los órganos de donantes más viejos conducen a una peor supervivencia del trasplante debido al aumento de las respuestas inmunes. La orientación de la interleucina-17A puede mejorar los resultados cuando se utilizan órganos de donantes más antiguos para el trasplante.